FDA reaffirms the therapeutic equivalence of Teva's extended-release bupropion tablets April 16 following a re-evaluation of the safety and efficacy for the antidepressant. FDA initiated the review of the generic version of GlaxoSmithKline's Wellbutrin XL (bupropion) after receiving 85 post-marketing reports in the first half of 2007. The majority of the reports involve loss of efficacy following a switch from the brand to generic product, which is manufactured by Impax. Other reports were for onset or worsening of side effects, consistent with the adverse effects in labeling. However, FDA concludes that Teva's 300 mg tablets, marketed as Budeprion XL, are bioequivalent and therapeutically equivalent to Wellbutrin XL, despite small differences in pharmacokinetic profiles. Impax is also approved for 100 mg, 150 mg and 200 mg dosages of extended-release bupropion. Other manufacturers of generic Wellbutrin XL include Sandoz, Anchen, Actavis and Watson
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Darko has become the first director-general of the AMA, an organization set up to transform access to quality-assured medicines across Africa and foster a more predictable, efficient regulatory environment for innovation.
Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.
Exclusive analysis by the Pink Sheet explores how non-submissions by pharmaceutical companies to England’s health technology appraisal body are impacting the availability of medicines on the National Health Service.
